Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2024-03-13 10:43:40
Oslo, 13 March 2024: Navamedic (OSE: NAVA) is pleased to welcome new
shareholders and delighted to see existing shareholders acquire a bigger stake
following Ingerø Reiten Investment Company's (IRIC) sale of its entire 17.1
percent interest in the company.
"IRIC has been an active owner in Navamedic since December 2018 when it became
our largest shareholder. During this period, we have transformed the company
into a profitable business with an attractive product portfolio, well positioned
for future growth. We have appreciated the cooperation and good support from
IRIC," said Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
Since 2019, Navamedic has almost tripled its turnover, reaching NOK 512 million
in 2023, and turned loss into profit. The company has built a diversified and
strong product portfolio through acquisitions and long-term distribution
agreements. Navamedic has proven its ability to develop new market opportunities
within the specialty pharma, hospital, and consumer health areas. The recent
acquisitions of Impolin AB and Sensidose AB have lifted the company into a new
era having own products with global potential.
"Our strategy has proven successful over the years, and the management team and
employees are keen to see profitable growth continue, both for the company and
to the benefit of our shareholders," Gamborg Andreassen concluded.
Management and leading employees together hold 16.7 per cent of the company's
shares and as a group represents the company's largest shareholder.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47917 62842
E-mail: lars.hjarrand@navamedic.com
About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit Navamedic.com.